This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Pediatric multiple sclerosis (MS) is clearly underrecognized and is often misdiagnosed as acute disseminated encephalomyelitis (ADEM), or as one of many relapsing pediatric neurologic conditions. Up to 5% of MS cases have a pediatric onset,1 and there are an estimated 10,000 cases in the United States alone.2 Recently, the International Pediatric MS Study Group proposed new clinical criteria for pediatric MS and related demyelinating disorders.3 However, definitive MRI criteria for these conditions are lacking. Recent studies have shown that at the time of their MS-defining attack, children meet McDonald MRI criteria only 67% of the time, suggesting a lower lesion burden at the time of presentation compared to adults.4 Previously published studies have suggested that the presence of periventricular and corpus callosum well-defined lesions may be sensitive predictors of MS after a first attack in childhood.5 Thus, neuroimaging biomarkers are powerful tools that may assist in both diagnosis and prognostication for demyelinating disorders in children.
In a pair of articles published in this issue of Neurology®, Callen and a well-recognized team of authors6,7 contrasted the MRI features of clinically definite MS in children with ADEM and with other neurologic diseases. In the first …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Costs and Utilization of New-to-Market Neurologic Medications
Dr. Robert J. Fox and Dr. Mandy Leonard